Experience

AlivaMab Biologics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Scientist

  • Nov 2022 - Present

• Scientist-II

  • Mar 2022 - Nov 2022



Gritstone bio

• United States
• Biotechnology Research
• 100 - 200 Employee

• Scientist-II, Antibody Discovery and Engineering

  • Feb 2021 - Mar 2022

• Scientist-I, Antibody Discovery

  • Jul 2019 - Feb 2021

  Emeryville, CA



Washington University School of Medicine in St. Louis

• Hospitals and Health Care
• 700 & Above Employee

• Postdoctoral Scholar

  • Jan 2019 - Jun 2019

  Saint Louis Current projects: (1) Antibody discovery using phage display technology against novel tumor specific targets; (2) Antibody production in mammalian as well as bacterial system; (3) Protein purification by chromatography (affinity, IEX, SEC) using AKTA FPLC and characterization of purified proteins; (4) Modifying and radiolabeling antibodies for in vitro and in vivo applications (imaging and therapy).



University of Missouri-Columbia

• United States
• Higher Education
• 700 & Above Employee

• Doctoral Researcher

  • Aug 2013 - Dec 2018

  Project 1: Discovery of novel tumor targeting antibody fragments (scFvs) using phage display • Panning and screening of scFv library for antigen binding properties. • Sub-cloning of antibody fragments into expression vector and purification of scFvs from bacterial and/or mammalian cell cultures by chromatography (IMAC, Protein L/G, Ion-exchange, Size exclusion). • Characterization of antibodies by electrophoresis, western blot, ELISA, flow cytometry (FACS), microscale… Show more Project 1: Discovery of novel tumor targeting antibody fragments (scFvs) using phage display • Panning and screening of scFv library for antigen binding properties. • Sub-cloning of antibody fragments into expression vector and purification of scFvs from bacterial and/or mammalian cell cultures by chromatography (IMAC, Protein L/G, Ion-exchange, Size exclusion). • Characterization of antibodies by electrophoresis, western blot, ELISA, flow cytometry (FACS), microscale thermophoresis (MST), and confocal microscopy. • Antibody engineering by site-directed mutagenesis or other amino acid based conjugated methods for downstream applications. • Radiolabeling of antibody fragments for in-vivo SPECT (67Ga, 99mTc) and PET (64Cu) imaging. Project 2: Development of click chemistry driven pretargeted cancer α-particle radioimmunotherapy • Purification of monoclonal antibodies from hybridoma cells using protein A chromatography. • Antibody conjugation and characterization by ELISA and various cell binding assays. • Develop methods to radiolabel pretargeting components with 212Pb. • Determine the in-vivo therapeutic response to the pretargeted RIT in tumor bearing mice injected with various doses of 212Pb. Show less